Key Points
- Director Robert Bessler sold 575,034 shares of LifeStance Health Group at an average price of $8.02, totaling about $4.61 million. After the sale, he still held 986,931 shares, but his position was reduced by 36.81%.
- LifeStance posted solid quarterly results, reporting EPS of $0.04 versus the expected $0.01 and revenue of $403.48 million, which beat estimates and rose 21.2% year over year.
- Analyst sentiment remains constructive, with multiple firms raising price targets or reiterating buy/overweight ratings. The stock’s average analyst rating is “Buy,” with an average price target of $9.86.
LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Eric Shuey sold 243,362 shares of the firm's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the transaction, the director directly owned 867,562 shares in the company, valued at approximately $6,957,847.24. The trade was a 21.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
LifeStance Health Group Price Performance
Shares of LFST opened at $7.89 on Friday. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.89. The firm has a market cap of $3.06 billion, a PE ratio of 131.50 and a beta of 1.20. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.65 and a current ratio of 1.48. The firm's 50 day moving average price is $6.87 and its 200 day moving average price is $6.78.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. The business's quarterly revenue was up 21.2% on a year-over-year basis. As a group, research analysts expect that LifeStance Health Group, Inc. will post 0.11 EPS for the current fiscal year.
LifeStance Health Group declared that its board has approved a share buyback plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.
Analysts Set New Price Targets
LFST has been the topic of a number of recent analyst reports. BTIG Research lifted their price target on shares of LifeStance Health Group from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, May 8th. Canaccord Genuity Group lifted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. UBS Group lifted their price target on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. KeyCorp lifted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an "overweight" rating in a research report on Thursday, February 26th. Finally, Zacks Research raised shares of LifeStance Health Group from a "hold" rating to a "strong-buy" rating in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $9.86.
View Our Latest Research Report on LFST
Trending Headlines about LifeStance Health Group
Here are the key news stories impacting LifeStance Health Group this week:
Institutional Investors Weigh In On LifeStance Health Group
Several hedge funds and other institutional investors have recently modified their holdings of LFST. Royal Bank of Canada grew its stake in shares of LifeStance Health Group by 63.4% in the first quarter. Royal Bank of Canada now owns 70,248 shares of the company's stock worth $468,000 after acquiring an additional 27,244 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of LifeStance Health Group by 223.0% in the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company's stock worth $343,000 after acquiring an additional 35,554 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company's stock worth $952,000 after acquiring an additional 4,169 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company's stock worth $4,100,000 after acquiring an additional 11,331 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company's stock worth $2,847,000 after acquiring an additional 51,154 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company's stock.
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
